Sisram Medical reported a 3.6% year-over-year revenue increase to $171.4 million in the first half of 2026, driven by stronger sales productivity and disciplined operations, though adjusted net profit fell to $5.04 million from $12 million a year earlier.
Gross profit totaled $97.2 million, with gross margin declining to 56.7% from 60% in H1 2025. Operating expenses rose 8.5% due to investments in China’s injectable business, including a new manufacturing facility in Beijing’s Miyun district that began production in June. Cash and cash equivalents stood at $77.3 million as of June 30.
Asia-Pacific revenue surged 19.1% to account for 45% of total sales, while international revenue excluding North America reached $127 million, up 16.7%. Injectable revenue jumped 54.2% to $22.2 million, with cumulative DAXXIFY shipments exceeding 30,000 vials across 28 Chinese provinces. The end-market price for DAXXIFY is RMB 6,800.
Europe revenue grew 12% to $26.7 million, and Canada operations expanded 20% year-over-year. Energy-based device revenue declined 2.5% to $134 million, though international sales excluding North America rose 7.2%. R&D investment totaled $8.5 million, with 24 clinical and pre-clinical studies conducted, including four new initiatives.
Shares fell 1.62% to $2.13 in Hong Kong trading, near the 52-week low of $2.10 and well below the high of $6.67. Executives emphasized a strategic shift toward integrated solutions, noting 2026 as a year of growth and integration amid geopolitical and supply chain considerations.
The company plans to submit Profhilo for registration in China in the second half of 2026, with approval expected in 2027.
